Oculis Holding AG is a biopharmaceutical company which develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidate includes OCS-01, OCS-02 and OCS-05. Oculis Holding AG is based in Zug, Switzerland.
| Revenue (Most Recent Fiscal Year) | $0.78M |
| Net Income (Most Recent Fiscal Year) | $-97.43M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1012.38 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.71 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -13815.93% |
| Net Margin (Trailing 12 Months) | -13788.70% |
| Return on Equity (Trailing 12 Months) | -92.95% |
| Return on Assets (Trailing 12 Months) | -70.03% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.79 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.14 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.77 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.41 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.64 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 43.66M |
| Free Float | -- |
| Market Capitalization | $851.42M |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | 0.27 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 22.30% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |